| INTRODUC TI ON
Interleukin-6 (IL-6) is a cytokine with a large variety of functions in disease and health. 1 Released together with other classic pro-inflammatory cytokines, such as tumour necrosis factor (TNF)-α, IL-6 appears to have deleterious effects on metabolism. [2] [3] [4] By contrast, when IL-6 is released together with metabolically beneficial hormones such as leptin, glucagon-like peptide-1 (GLP-1) and amylin,
IL-6 appears to have positive effects on metabolism. [5] [6] [7] [8] [9] IL-6 is not only produced in adipose tissue, in skeletal muscle during exercise and in immune cells, but also is abundant in the central nervous system (CNS). 1, 5, [10] [11] [12] The membrane bound IL-6 receptor, IL-6 receptor-alpha (IL-6Rα) is expressed in a major portion of fundamental energy-regulatory hypothalamic nuclei in the healthy mouse brain, mainly in neurones, thus forming an anatomical basis for the local effects of IL-6. [13] [14] [15] [16] IL-6 −/− mice develop mature-onset obesity at around 6 months of age. 17 Intracerebroventricular administration (but not peripheral administration) of IL-6 decreases body fat in rodents, suggesting that the anti-obesity effect of IL-6 is exerted at the level of the CNS. 18, 19 Central IL-6 has been shown to play a role in the anti-obesity effects of GLP-1 analogues, such as exendin-4 (Ex-4), mainly via reduced food intake. 20, 21 In the hypothalamus and hindbrain, IL-6 appears to act as a downstream mediator for the effects of GLP-1R-stimulation, 21 as well as amylin action. 5 Thus, IL-6 may act as a regulator of anorexia and body weight in healthy animals. In addition, the cachexia observed in various diseases appears to depend partially on IL-6 release. 2, 22, 23 In mouse cancer models, blocking of IL-6 synthesis has been shown to attenuate cachexia progression. 24 GLP-1, a post-translational proglucagon product, is a neuropeptide produced peripherally in ileal L-cells of the intestine, as well as centrally in preproglucagon (PPG) neurones of the nucleus of the solitary tract (NTS). 25 GLP-1 production causes an increase of insulin release from pancreatic β-cells and a decrease of glucagon release from pancreatic α-cells. GLP-1 has a very short half-life in serum because it is rapidly degraded by the enzyme dipeptidyl-peptidase 4. However, long acting GLP-1 analogues used to treat obesity and type 2 diabetes, such as Ex-4, are less easily degraded. 26, 27 GLP-1 and the ability of its analogues to increase insulin secretion and control blood glucose levels, as well as their anti-obesity effects, have been widely explored. 20, [28] [29] [30] However, the potential for IL-6 to act as a downstream signalling peptide of GLP-1
has not yet been fully explored. It has been observed that GLP-1 analogues decrease food intake as well as body weight. Previous studies have reported that these anorexic effects are exerted at the level of the CNS 27, 31, 32 and it has been suggested that GLP-1 may act on POMC/CART expressing neurones in the arcuate nucleus of the hypothalamus. 33 Moreover, peripheral GLP-1 and its analogues have been reported to cross the blood-brain barrier, making the central GLP-1 receptor (GLP-1R) a possible pharmaceutical target. 34, 35 GLP-1Rs are highly expressed in energy-balance-regulating areas, such as the hypothalamus, hindbrain and amygdala. 36 It is likely that the principal source of ligand to these receptors is the GLP-1-producing-neurones of the NTS that produce PPG, a precursor for e g GLP-1. Furthermore, it has been shown that PPG-projections reach, among other nuclei, the central amygdala (CeA). 28 The
CeA is involved in fear-, stress-and drug-related responses. 37 Aside from these functions, the CeA was implied to be important in regulation of food intake and energy expenditure. 38 Bilateral lesions of the amygdala in rats induce hyperphagia and weight gain, further supporting its role as an anorexigenic nucleus. 
| Tissue preparation for immunohistochemistry
Mice were deeply anaesthetised and perfused transcardially with heparinised saline (50 IU mL 
| Immunohistochemistry
Briefly, sections were rinsed in wash buffer (0. Figure S1 ).
| Confocal microscopy and cell counting
Images of the stained sections were obtained using either a confocal microscope system (LSM 700; Carl Zeiss, Oberkochen, Germany), together with a Plan APO ×40 A/1.40 oil lens (Nikon, Tokyo, Japan) (for close-up pictures) or a Plan Fluor ×20/0.75 lens (for anatomical overview pictures) and a solid-state laser. For co-localisation, focus stacking was used to achieve a greater depth of field. Micrographs were adjusted for brightness and contrast in fiji 46 and overview slides were constructed using a fiji plug-in. from these animals were used to construct images. Student's t test was used to determine statistical significance of the differences in co-localisation.
| Electrophysiology
Rats were anaesthetised using isoflurane inhalation. The brain was removed rapidly and immersed in ice-cold sodium-free solution.
22
Acute 300-μm-thick coronal slices containing the CeA were prepared with a VT-1000S vibratome (Leica) in the sodium-free solution and then equilibrated in normal artificial cerebral spinal fluid
and 10 mmol L -1 glucose, bubbled with O 2 /CO 2 ). Loose-patch clamp measurements to record action currents were carried out as described previously 23 with slight modifications. Briefly, pipette potential was held at 0 mV, pipette resistance 1-2 MΩ and resistance of loose-patch seal 7-40 MΩ. The pipette solution con-
Hepes and 10 mmol L -1 glucose (pH 7.3; with NaOH). CeA was identified under microscopic control.
Measurements were carried out with an initial control recording (4 minutes); then, in the first experimental group of neurones, IL-6
(1 nmol L -1 ) was added to the normal aCSF by a single bolus into the recording chamber, and the recording continued for a subsequent 11 minutes. In a second experimental group of neurones, a cocktail of IL-6 and a IL-6 neutralising antibody (1 mol L -1 ; Tocris Bioscience, St Louis, MO, USA) was applied after the initial recording of basal firing. Each neurone served as its own control when drug effects were evaluated. 
| RNA isolation and mRNA expression

| In situ hybridisation
For RNAscope® (ACD, Newark, CA, USA) investigations, central amygdala containing brain sections (12 μm thick) were cut and fixed in 10% formalin (Thermo Fisher Scientific) for 30 minutes. To test the effects of IL-6, rats were injected with IL-6 (0.2 or 1 μg per 0.5 μL) or vehicle (aCSF). Rats were food-restricted to 50%
of their normal intake overnight. Chow intake was measured 1, 3 and 6 hours after injection. Each treatment was counterbalanced, where each condition was separated by a minimum of 2 days.
| Statistical analysis
Graphs were constructed using prism, version 8 (GraphPad Software Inc., San Diego, CA, USA). Statistical analyses were conducted using Students t test. P < 0.05 was considered statistically significant. Using the novel RedIL6 reporter mouse strain, we found a pattern of fluorescence similar to that with the anti-IL-6 antibody staining ( Figure 3A ,B).
| RE SULTS
| GLP-1 is present in synapses close to IL-6 fluorescent cells
PPG-reporter (Venus) mice were co-stained with IL-6 and synaptophysin antibodies to determine whether PPG-synapses were present near IL-6 cells in the CeA (Figure 4 ). We found examples of cells where triple co-localisation was present, suggesting that some PPG-fibres formed synapses with IL-6-immunoreactive cells ( Figure 4D-F) .
| Central Ex-4 administration increases IL-6 mRNA expression in the CeA
Administration of Ex-4 (3 mg kg ) to the lateral ventricle of mice resulted in a statistically significant 50% increase in IL-6 mRNA-expression after 90 minutes compared to vehicle (aCSF) controls (P = 0.04) ( Figure 3C ).
| IL-6Rα is present in NeuN-immunoreactive cells in the central amygdala and IL-6 stimulates the firing rate of neurones in the capsular part of the CeA
IL-6Rα antibody was co-stained with the neurone marker NeuN. We found co-localisation between the two antibodies in the CeA, mainly in 12 neurones/12 brain slices/five rats) ( Figure 5E ) and this significant (P < 0.05, Student's t test) elevation was mostly because the decrease in the time between bursts resulted in a high-frequency tonic firing.
The effect of IL-6 lasted for approximately 10 minutes ( Figure 5E ).
Repeated administration of IL-6 approximately 5 minutes after return-
ing of the frequency to its baseline level resulted in no change. These data are in accordance with the results of Fischer et al 52 demonstrat-
ing that IL-6 has rendered cells insensitive to further administration of IL-6 for several hours. In a second experiment, IL-6 was pre-incubated with an IL-6 neutralising antibody for 30 minutes, followed by administration of this cocktail to CeA slices. This resulted in a significant dampening of the effect induced by IL-6 only on the mean firing rate (160 ± 35%; P < 0.05; 10 neurones/10 slices/four rats) ( Figure 5F ).
| IL-6 administration to CeA slightly reduces 1-hour chow intake in overnight-restricted rats
Administration of 0.2 or 1 μg (Figure 6 ) of IL-6 to the CeA in rats slightly decreased 1-hour chow intake ( Figure 6A ).
By contrast to the 1-hour time point, there was no effect on 3-hour ( Figure 6B ) or 6-hour ( Figure 6C ) chow intake after IL-6 administration. The reduction of food intake was seen in animals that had been fasted overnight, whereas there was no effect in ad lib. fed animals (not shown). Administration of an IL-6/CGRP cocktail did not potentiate the suppression of food intake seen in IL-6 treated and food-restricted rats (not shown).
| D ISCUSS I ON
| Potential interactions between GLP-1 and IL-6 in the CeA
Formerly, the amygdala has been seen mainly as a nucleus important for fear-and stress conditioning. 37 However, recently, it has also been implicated as important for the regulation of energy balance, including In the present study, we used RedIL6, an IL-6 reporter mouse that was described recently. 42 Briefly, the RedI6 reporter mouse was 
| The presence of functional IL-6Rα in the CeA
IL-6Rα immunoreactivity was present in over half of the CeA cells with NeuN (a neuronal marker) immunoreactivity. This is consistent with the previously reported co-localisation of these two antibodies in both the hypothalamus and hindbrain. [13] [14] [15] [16] 55 We next determined whether these receptors were functional. Using electrophysiology, we found that these receptors indeed responded to IL-6 treatment with an increased firing rate and that this effect could be attenuated
by an IL-6 neutralising antibody.
Further support for functional IL-6Rα in CeA came from the finding that administration of IL-6 to the CeA partially inhibited feeding.
The latter finding is in line with studies by Timper et al 6 reporting a similar effect after i.c.v. administration. However, further studies are needed to fully determine whether or not IL-6 is an important player in amygdala energy balance regulation.
| Summary
Taken together, our data indicate that IL-6 is present in approxi- 
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